Sort   by:  
 Page size 
UnknownPREOPERATIVE TREATMENT WITH METYRAPONE IN PATIENTS WITH CUSHING'S SYNDROME DUE TO ADRENAL ADENOMA.
Not available
S-EPMC6215797 | biostudies-literature
UnknownPhase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma.
Not available
S-EPMC9058897 | biostudies-literature
UnknownEffects of Germline CYP2W1*6 and CYP2B6*6 Single Nucleotide Polymorphisms on Mitotane Treatment in Adrenocortical Carcinoma: A Multicenter ENSAT Study.
Not available
S-EPMC7072643 | biostudies-literature
UnknownDifferential Expression Profiles of Cell-to-Matrix-Related Molecules in Adrenal Cortical Tumors: Diagnostic and Prognostic Implications.
Not available
S-EPMC8148197 | biostudies-literature
UnknownIntermittent everolimus administration for malignant insulinoma.
Not available
S-EPMC4174591 | biostudies-literature
UnknownCYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells.
Not available
S-EPMC5937768 | biostudies-literature
UnknownGlucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant.
Not available
S-EPMC8764187 | biostudies-literature
UnknownAdjuvant platinum-based chemotherapy in radically resected adrenocortical carcinoma: a cohort study.
Not available
S-EPMC8548516 | biostudies-literature
UnknownRelacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study.
Not available
S-EPMC8317576 | biostudies-literature
UnknownAlbumin/Mitotane Interaction Affects Drug Activity in Adrenocortical Carcinoma Cells: Smoke and Mirrors on Mitotane Effect with Possible Implications for Patients' Management.
Not available
S-EPMC10706292 | biostudies-literature
Sort   by:  
 Page size